

Glycostem enters into Material Transfer Agreement with Pieris to enhance solid tumor targeting capabilities of Glycostem's oNKord® and CAR-NK treatments

Oss, the Netherlands – 12th March, 2021 – Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic allogeneic off-the-shelf Natural Killer (NK) cells, has entered into a material transfer agreement with Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications to study the potential of Pieris' Anticalin technology to enhance the activity of Glycostem's lead product oNKord®, which is based on non-manipulated NK cells.

Under the terms of the agreement, Pieris will provide Glycostem with Anticalin constructs against immune targets to be combined with Glycostem's oNKord® technology to study the combined potential of the technologies in the treatment of solid tumors. The parties are also exploring unique NK-based chimeric antigen receptor (CAR-NK) treatments using Glycostem's CAR-NK technology, viveNK™, and Pieris' Anticalin platform to investigate new tumor targeting approaches.

“We look forward to study the potential benefits of combining our NK cell and CAR-NK products with Pieris Anticalin technology in the treatment of solid tumors. We believe these research efforts could lead to novel applications for oNKord® in the field of solid tumor NK cell immunotherapy. Our ultimate goal is to offer these pioneering therapies to patients with the hopes of curing cancer,” said Troels Jordansen, CEO of Glycostem. “Besides, we are glad to reach this significant agreement which marks Glycostem's first US agreement and confirms our increasing focus on the US market.”

About Glycostem

Netherlands-based Glycostem Therapeutics B.V., a clinical stage biotech company, developing allogeneic cellular immunotherapies to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem's products are a safe alternative to CAR-T-cells. Glycostem's lead product, oNKord[®], is manufactured from allogeneic raw material and is available off-the shelf. Thanks to its nine patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market with off-the-shelf products.

oNKord[®] is produced in a closed system (uNiK[™]) in Glycostem's state-of-the-art and GMP (Good Manufacturing Practice) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes *ex vivo* generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord[®] successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). A phase I/IIa (pivotal) clinical trial is on-going to evaluate the safety and efficacy of oNKord[®] in patients with AML. Glycostem is furthermore developing a range of CAR-NK and TCR-NK products in-house and in cooperation with global partners. For more information, visit www.Glycostem.com.

oNKord[®] is a registered trademark of Glycostem in the US and Europe. viveNK[™] and uNiK[™] are pending trademarks of Glycostem.

Glycostem Therapeutics BV

Troels Jordansen

Tel +31 6 1834 5326

Troels@Glycostem.com

About Pieris Pharmaceuticals

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Pieris pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin[®] is a registered trademark of Pieris. For more information, visit www.pieris.com.

Pieris Pharmaceuticals, Inc.

Maria Kelman

Executive Director, Investor Relations

+1 857 362 9635

kelman@pieris.com